Pharmaceutical

AHA 2024: Tirzepatide improves outcomes for major heart failure with HFpEF and obesity in SUMMIT

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP/GLP-1).

Nov 19, 2024 - 06:00
AHA 2024: Tirzepatide improves outcomes for major heart failure with HFpEF and obesity in SUMMIT
Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP/GLP-1).
Read the original article

Tags:

Previous Article

Bavarian Nordic shares sink by 12% after mpox sales slump in Q3

Next Article

CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmacies fear New Year’s financial squeeze from Biden administration rule

STAT+: Pharmacies fear New Year’s financial squeeze fro...

Jan 2, 2024

Newly launched Calluna raises $81m to advance monoclonal antibody pipeline

Newly launched Calluna raises $81m to advance monoclona...

Jan 23, 2024

Opinion: PAs need a new name, but ‘physician associate’ won’t cut it. Here’s a better idea

Opinion: PAs need a new name, but ‘physician associate’...

Jun 2, 2023